Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Even when placed incorrectly on the top of the tongue instead of under it, Anaphylm (AQST-109) sublingual epinephrine still produced clinically meaningful pharmacodynamic effects. Blood pressure changes actually exceeded those seen with manual intramuscular epinephrine, despite lower drug absorption. The findings are part of Aquestive Therapeutics' resubmission package to the FDA following a complete response letter earlier this year.
Even when patients place Anaphylm (AQST-109) on the top of their tongue instead of under it, the sublingual epinephrine film still delivers clinically meaningful results. Data presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting showed that while incorrect placement reduced drug absorption (pharmacokinetics), the real-world physiological effects (pharmacodynamics) — like changes in blood pressure and heart rate — remained robust and in some cases exceeded those seen with manual intramuscular epinephrine.
This matters because real-world patients may not always administer the film perfectly, and these findings offer reassurance that the drug can still work even under non-ideal conditions. The study also confirmed that self-administration without training produced pharmacokinetic results comparable to — or better than — healthcare provider administration.
Key Takeaways
Why it matters: These findings directly address FDA concerns about real-world usability of Anaphylm, and the data have been submitted as part of Aquestive's FDA resubmission package — a key step toward potential approval of a needle-free anaphylaxis treatment option.